BB Biotech AG (XSWX:BION) Cash-to-Debt : 0.00 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BB Biotech AG's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, BB Biotech AG couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for BB Biotech AG's Cash-to-Debt or its related term are showing as below:

During the past 13 years, BB Biotech AG's highest Cash to Debt Ratio was 0.30. The lowest was 0.00. And the median was 0.11.

XSWX:BION's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.485
* Ranked among companies with meaningful Cash-to-Debt only.

BB Biotech AG Cash-to-Debt Historical Data

The historical data trend for BB Biotech AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BB Biotech AG Cash-to-Debt Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.21

0.11

0.01

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of BB Biotech AG's Cash-to-Debt

For the Biotechnology subindustry, BB Biotech AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BB Biotech AG's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cash-to-Debt falls into.

BB Biotech AG Cash-to-Debt Calculation

This is the ratio of a company's Balance Sheet Cash And Cash Equivalents to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BB Biotech AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Balance Sheet Cash And Cash Equivalents	/	Total Debt
	=	Balance Sheet Cash And Cash Equivalents	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.501	/	(0	+	304.9)
	=	0.00

BB Biotech AG's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Balance Sheet Cash And Cash Equivalents	/	Total Debt
	=	Balance Sheet Cash And Cash Equivalents	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.501	/	(0	+	304.9)
	=	0.00

BB Biotech AG (XSWX:BION) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BB Biotech AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (XSWX:BION) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

Executives

Prof. Dr. Mads Krogsgaard Thomsen

Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines